Tag Archives: Medicaid

AMCP Talk Pricing of Specialty Pharma Spurred by Sovaldi

Starting off this week’s Academy of Managed Care Pharmacy (AMCP) meeting in Boston, experts including patient access advocates, pharma and payer representatives came together for this year’s symposium entitled “Specialty Pharmacy and Patient Care: Are We at a Tipping Point?”
Posted in healthcare, Market Access, pricing | Also tagged , , , , , , | Leave a comment

Physicians Won’t Change Their Practices Without Worthwhile Incentives

By Mark Wagar. (This blog first appeared on Managed Healthcare Executive.) There is more collaboration than ever between payers and providers in the drive to provide high-quality, cost-effective care to diverse populations across the United States. According to a January 2014 Centers for Medicare and Medicaid Services (CMS) report, the accountable care organization (ACO) model is […]
Posted in Guest Blog, healthcare, Regulatory | Also tagged , , , , , | Leave a comment

The Sovaldi Case: Is American Biotech History About to Repeat Itself?

Recent Congressional investigations over the pricing scheme of Gilead’s much-heralded hepatitis C drug Sovaldi – and a decline in stocks across the biotech sector – rings a familiar bell, writes Tom Norton. Twenty years ago in May, US Senator Joe Lieberman carefully questioned biotech CEO Harry Penner of then Neurogen Corporation about why his company’s […]
Posted in Biotech, healthcare, leadership, Market Access, pricing, R&D, Sales, Strategy | Also tagged , , , , , , , , | 2 Comments

Budget Options Will Reshape Healthcare

While the struggle continues in 2014 to provide effective and affordable coverage, administration and Congressional leaders will weigh a host of spending options important to coverage and delivery. Federal outlays for healthcare and health-related federal tax benefits exceed $1 trillion a year, according to the Congressional Budget Office (CBO). These and related spending on discretionary […]
Posted in Guest Blog, healthcare, Regulatory | Also tagged , , | Leave a comment

Obamacare and U.S. Pharma: Two Months In

U.S. Pharma in the Eye of the Obamacare Storm So, we’ve experienced two months of Obamacare.  How is the U.S. pharmaceutical industry doing with this new program?  I spent two weeks getting the opinions of several Rx representatives on their experience with Obamacare, as well as their thoughts on how it is impacting their marketing, […]
Posted in Guest Blog, healthcare, Op-Ed, Regulatory | Also tagged , , | 1 Comment
  • Categories

  • Meta